PerkinElmer agrees to acquire Sirion Biotech

By The Science Advisory Board staff writers

June 22, 2021 -- PerkinElmer has entered into an agreement to acquire Sirion Biotech, a provider of viral vector-based technology for cell and gene therapies. The acquisition is expected to close during the third quarter of 2021.

Sirion is headquartered in Munich and has approximately 50 employees based in Germany, the U.S., and France. The company has established over a dozen licensing agreements with major pharmaceutical and biotech companies addressing more than 25 diseases and conditions.

Sirion's viral vector offerings will complement PerkinElmer's Horizon Discovery portfolio, which includes gene editing and modulation tools for CRISPR, CRISPR interference, and RNA interference (RNAi), custom cell lines, and base editing technologies. The acquisition will also further broaden PerkinElmer's existing cell and gene research solutions, including in vivo and cell painting screening technologies, immunoassays, and cell plate readers, as well as automation, microfluidics, informatics, and analytical platforms.

"By combining Sirion's innovative 'payload' transport technology with our existing Horizon genetic material editing tools and phenotypic research solutions, we will be able to support organizations' cell and gene therapy workflows as they look to streamline and accelerate their efforts," commented Prahlad Singh, PhD, president and CEO of PerkinElmer.

Financial details of the acquisition were not disclosed.

PerkinElmer contributes resources to public cell painting dataset
PerkinElmer is providing its PhenoVue cell painting kits to the Joint Undertaking in Morphological Profiling-Cell Painting consortium to help speed drug...
PerkinElmer to acquire Nexcelom for $260M
PerkinElmer has entered into an agreement to acquire life sciences instrumentation firm Nexcelom Bioscience for $260 million, a deal that is expected...
PerkinElmer posts major gains in Q1
PerkinElmer reported sharp increases in revenues and net income for the first quarter of 2021.
PerkinElmer contributes to PROTACs research
PerkinElmer is serving as a provider and co-developer of assays, instruments, and expertise for the ProxiDrugs Consortium, which is zeroing in on research...
Horizon Discovery offers new CRISPR reagents
Horizon Discovery, a PerkinElmer company, is expanding its gene editing and modulation portfolio to include a new family of CRISPR modulation reagents...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter